ARGNF.US argenx SE

Healthcare Biotechnology USA Stocks
900.30 USD
Close of Nov 13, 2026
712.03 1,020
Market cap
USD 56.6B
P/E
31.2x
P/B
6.73x
ROE
21.3%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is ARGNF.US undervalued?

Graham number

The Graham number of argenx SE cannot be estimated reliably (the estimate is too far from the market price).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

argenx SE fundamental analysis

No fundamental analysis for argenx SE yet.

argenx SE stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About argenx SE

argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative gMG, ocular myasthenia gravis …

Full company profile